VALLEY CHILDRENS HOSPITAL
- Type
- Teaching hospital
- Where
- MADERA, CA
- Medicare CCN
- 053300
- Received
- $170,309 in 38 records, 2019 ($4,331 general, $165,977 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: VALLEY CHILDRENS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 10 | $4,331 |
| 2019 | Research payment | 28 | $165,977 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | 4 | $133,599 | 2019 |
| Eisai Inc. | 3 | $25,644 | 2019 |
| PFIZER INC. | 3 | $2,397 | 2019 |
| E.R. Squibb & Sons, L.L.C. | 1 | $1,500 | 2019 |
| Abbott Laboratories | 3 | $1,255 | 2019 |
| Incyte Corporation | 8 | $1,103 | 2019 |
| AstraZeneca Pharmaceuticals LP | 2 | $1,000 | 2019 |
| Stryker Corporation | 1 | $709 | 2019 |
| Insulet Corporation | 1 | $500 | 2019 |
| LIFESCAN, INC. | 1 | $500 | 2019 |
| Lilly USA, LLC | 1 | $500 | 2019 |
| COLOPLAST CORP | 1 | $500 | 2019 |
| Ipsen Biopharmaceuticals, Inc | 1 | $500 | 2019 |
| Merck Sharp & Dohme LLC | 4 | $285 | 2019 |
| Novo Nordisk AS | 2 | $192 | 2019 |
| Masimo Corporation | 2 | $121 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 28 | $165,977 |
| Space rental or facility fees (teaching hospital only) | 5 | $2,500 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $1,000 |
| Gift | 1 | $709 |
| Education | 2 | $121 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Stryker Corporation | $709 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-31 | Masimo Corporation | $118 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $2 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-10 | Novo Nordisk AS | $117 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-12-10 | Novo Nordisk AS | $75 | Research payment | In-kind items and services | Sogroya Biological, Growth Hormone | NN8640-4263 | 2019 |
| 2019-12-09 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-11-16 | Ipsen Biopharmaceuticals, Inc | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DYSPORT Drug, Neurology | 2019 | |
| 2019-10-10 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-10-08 | COLOPLAST CORP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SPEEDICATH Device, CONTINENCE | 2019 | |
| 2019-10-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-10-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-08-29 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-08-02 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2019 |
| 2019-07-25 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-06-27 | E.R. Squibb & Sons, L.L.C. | $1,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Nivo in HL Pediatric nivo bv | 2019 |
| 2019-06-18 | Eisai Inc. | $500 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat | 2019 |
| 2019-06-18 | Eisai Inc. | $200 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat | 2019 |
| 2019-06-13 | Abbott Laboratories | $255 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-05-23 | Eisai Inc. | $24,944 | Research payment | Cash or cash equivalent | Fycompa Drug, Neurology | A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat | 2019 |
| 2019-05-02 | Insulet Corporation | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-05-01 | PFIZER INC. | $1,776 | Research payment | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 |
| 2019-05-01 | PFIZER INC. | $414 | Research payment | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 |
| 2019-05-01 | PFIZER INC. | $207 | Research payment | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 |
| 2019-04-28 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Drug, Respiratory | 2019 | |
| 2019-03-06 | LIFESCAN, INC. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OneTouch Device, Diabetes Testing | 2019 | |
| 2019-02-25 | Lilly USA, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-02-22 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2019 |
| 2019-01-31 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Drug, Respiratory | 2019 | |
| 2019-01-25 | VERTEX PHARMACEUTICALS INCORPORATED | $2,156 | Research payment | Cash or cash equivalent | ORKAMBI Drug, CYSTIC FIBROSIS | A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who Com | 2019 |
| 2019-01-10 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2019 |
| 2019-01-07 | Merck Sharp & Dohme LLC | $82 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2019 |
| 2019-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | $92,289 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | 2019 | |
| 2019-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | $29,373 | Research payment | Cash or cash equivalent | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and | 2019 | |
| 2019-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | $9,780 | Research payment | Cash or cash equivalent | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Madera, CA, county Madera County, CA, state California; placed by its city name.
| Measure | Place (city or town) Madera, CA | County Madera County, CA | State California |
|---|---|---|---|
| Population B01003 | 67,831 | 160,940 | 39,287,377 |
| Population, 2020 census P1 | 66,224 | 156,255 | 39,538,223 |
| Median age B01002 | 30.4 | 34.6 | 37.9 |
| Under 18 B01001 | 30.8% | 27.1% | 22.0% |
| 65 and over B01001 | 9.6% | 14.4% | 15.7% |
| Households B11001 | 17,526 | 45,379 | 13,548,091 |
| Foreign born B05002 | 25.6% | 20.1% | 27.0% |
| Median household income B19013 | $63,933 | $76,627 | $99,122 |
| Median family income B19113 | $67,479 | $83,389 | $113,346 |
| Per capita income B19301 | $24,200 | $30,077 | $49,513 |
| Poverty rate B17001 | 25.6% | 19.2% | 12.0% |
| Unemployment rate B23025 | 12.6% | 10.1% | 6.6% |
| Civilian labor force B23025 | 29,997 | 69,012 | 20,068,466 |
| Mean commute (minutes) B08013 | 25.7 | 27.9 | 28.7 |
| Bachelor's degree or higher B15003 | 10.9% | 17.9% | 37.1% |
| Housing units B25001 | 18,562 | 51,015 | 14,644,735 |
| Owner-occupied B25003 | 54.7% | 67.5% | 55.9% |
| Renters B25003 | 45.3% | 32.5% | 44.1% |
| Median home value B25077 | $359,900 | $393,200 | $734,700 |
| Median gross rent B25064 | $1,353 | $1,390 | $2,036 |
| White, not Hispanic B03002 | 12.2% | 29.9% | 33.8% |
| Black B03002 | 2.9% | 2.4% | 5.2% |
| Hispanic or Latino B03002 | 81.1% | 60.9% | 40.2% |
| Asian B03002 | 1.3% | 2.4% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.
Comments